Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
507
Recruiting, any sponsor type, condition "gastric"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting507
- Completed1,614
507 trials
Showing 1 to 25, recently updated first.
Qilu Hospital of Shandong UniversityAcademic, hospital or other
NCT06932068 · 77 participants (planned) · Start Mar 26, 2025 · Primary completion Oct 31, 2027
Drug: Iparomlimab and Tuvonralimab (QL1706); Oxaliplatin and 1 more · For: HER2 Negative; Low PD-L1 Expressing; Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Sites: Zhengzhou, China; Binzhou, China; Dezhou, China · 29 sites in all
- GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant AscitesPivotal-lookingRecruiting
Kyushu UniversityAcademic, hospital or other
NCT05438459 · 176 participants (planned) · Start Jun 8, 2022 · Primary completion Mar 31, 2032
Drug: GAIA-102; GAIA-102 and 6 more · For: Gastric Cancer; Pancreatic Cancer
Sites: Fukuoka, Japan
- Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07392892 · 840 participants (planned) · Start May 14, 2026 · Primary completion Jul 22, 2031
Drug: PF-08634404; Chemotherapy and 1 more · For: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma; Metastatic Gastric Cancer; Gastroesophageal Junction Cancer and 1 more
Sites: Anaheim, California; Atascadero, California; Burbank, California · 124 sites in all
Haihua YuanAcademic, hospital or other
NCT07631884 · 15 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2028
Drug: Trastuzumab Rezetecan · For: Solid Tumors; Neoplasms (Cancer / Tumors); Advanced Malignant Solid Neoplasm and 13 more
Sites: Shanghai, China
- Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal MetaplasiaPivotal-lookingRecruiting
Yongquan ShiAcademic, hospital or other
NCT06610266 · 400 participants (planned) · Start Feb 28, 2025 · Primary completion Dec 31, 2027
Drug: Weifuchun; Folic Acid · For: Gastric Intestinal Metaplasia
Sites: Shangluo, China; Ankang, China; Tongchuan, China · 10 sites in all
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalAcademic, hospital or other
NCT07951658 · 12 participants (planned) · Start Sep 27, 2026 · Primary completion Oct 2028
Drug: Tirzepatide · For: Diabetes Type I
Sites: Madrid, Spain
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruiting
National Cancer Institute (NCI)NIH
NCT06503146 · 320 participants (planned) · Start Sep 9, 2025 · Primary completion Jun 1, 2028
Drug: [18F]FAPI-74; [18F]FDG · For: Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma and 7 more
Sites: Bethesda, Maryland
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
Northwestern UniversityAcademic, hospital or other
NCT07594548 · 18 participants (planned) · Start Nov 10, 2026 · Primary completion Sep 9, 2030
Drug: Futibatinib; Paclitaxel and 1 more · For: Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8 and 13 more
Sites: Chicago, Illinois; Columbus, Ohio
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07488676 · 150 participants (planned) · Start May 4, 2026 · Primary completion Jul 31, 2029
Drug: ASP546C · For: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 35 sites in all
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07685808 · 360 participants (planned) · Start Jul 28, 2026 · Primary completion Jan 21, 2028
Drug: Olatorepatide; Placebo · For: Overweight or Obesity
Sites: Mobile, Alabama; Walnut Creek, California; Waterbury, Connecticut · 22 sites in all
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on TumorsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07863024 · 320 participants (planned) · Start Oct 28, 2026 · Primary completion Mar 10, 2031
Drug: REGN13089-M404-M2980 · For: Advanced Solid Tumors
Sites: Huntersville, North Carolina
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07845578 · 60 participants (planned) · Start Sep 25, 2026 · Primary completion Sep 11, 2027
Drug: Semaglutide; Placebo semaglutide and 1 more · For: Obesity; Overweight
Sites: Graz, Austria
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06172478 · 890 participants (planned) · Start Feb 26, 2024 · Primary completion Nov 19, 2030
Drug: HER3-DXd · For: Advanced Solid Tumor; Melanoma; Head and Neck Cancer and 11 more
Sites: Duarte, California; New Haven, Connecticut; Kissimmee, Florida · 97 sites in all
Iambic Therapeutics, IncIndustry
NCT06253871 · 463 participants (planned) · Start Mar 25, 2024 · Primary completion Oct 2028
Drug: IAM1363; Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab and 3 more · For: HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer and 10 more
Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 53 sites in all
- GMPA Versus PPI for Gastric Protection and aGVHD RiskPivotal-lookingRecruiting
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT07791849 · 198 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 15, 2028
Drug: Teprenone; Esomeprazole · For: Hematopoietic Stem Cell Transplantation (HSCT); aGVHD; Infection and 2 more
Sites: Hangzhou, China
- A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.Recruiting
PfizerPfizer (PFE)
NCT07903415 · 280 participants (planned) · Start Nov 5, 2026 · Primary completion Jan 26, 2031
Drug: PF-08098488 · For: Pancreatic Ductal Adenocarcinoma; Esophageal Cancer; Carcinoma, Non-Small-Cell Lung (NSCLC) and 2 more
Sites: Grand Rapids, Michigan; Nashville, Tennessee; San Antonio, Texas · 4 sites in all
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06324357 · 910 participants (planned) · Start Jun 28, 2024 · Primary completion Jan 8, 2029
Drug: Zongertinib; Trastuzumab deruxtecan and 6 more · For: Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma and 2 more
Sites: Cerritos, California; Los Angeles, California; Orange, California · 105 sites in all
- Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction AdenocarcinomaPivotal-lookingRecruiting
National Cancer Center, JapanGovernment (non-federal)
NCT07699939 · 136 participants (planned) · Start Jul 15, 2026 · Primary completion Nov 30, 2028
Drug: serplulimab; Placebo · For: Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma
Sites: Chiba, Japan; Fukuoka, Japan; Gifu, Japan · 19 sites in all
- Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal CavityPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT07001748 · 148 participants (planned) · Start Oct 24, 2025 · Primary completion May 30, 2030
Drug: Standard of Care Chemotherapy; Intraperitoneal Paclitaxel · For: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Peritoneal Carcinomatosis
Sites: Irvine, California; Los Angeles, California; Orange, California · 78 sites in all
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06469944 · 160 participants (planned) · Start Sep 20, 2024 · Primary completion Sep 12, 2029
Drug: Pembrolizumab; Sacituzumab Tirumotecan (sac-TMT) and 6 more · For: Gastroesophageal Junction; Gastroesophageal Adenocarcinoma; Esophageal Neoplasms and 1 more
Sites: Tucson, Arizona; Los Angeles, California; Louisville, Kentucky · 50 sites in all
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.Industry
NCT07923214 · 66 participants (planned) · Start Jul 2, 2024 · Primary completion Apr 2027
Drug: CG-7321; Fulvestrant and 1 more · For: Advanced Solid Tumors; Breast Cancer; Ovarian Cancer and 2 more
Sites: Fuzhou, China; Dalian, China; Shanghai, China · 4 sites in all
EMD Serono Research & Development Institute, Inc.Industry
NCT07360314 · 138 participants (planned) · Start Feb 13, 2026 · Primary completion Sep 28, 2028
Drug: M7437; M7437 · For: Advanced Solid Tumors
Sites: New Haven, Connecticut; Huntersville, North Carolina; Galveston, Texas · 9 sites in all
University of California, Los AngelesAcademic, hospital or other
NCT07168395 · 68 participants (planned) · Start Oct 1, 2026 · Primary completion Nov 2027
Drug: Non-selective beta blockers · For: Gastric Varices
Sites: Los Angeles, California
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.